ArticleFrontiers in pharmacology2018
Correction of Anemia in Chronic Kidney Disease With
Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Effects of Jianpi Bushen Therapy for Treatment of CKD Anemia: A Meta-Analysis of Randomized Controlled Trials.Frontiers in pharmacology · 2020Pooled it
- Chinese Herbal Medicine Significantly Impacts the Haematological Variables of the Athlete Biological Passport.International journal of environmental research and public health · 2021Trial
- Iron, ESA, and HIF-Inhibitors: Are There Other Opportunities to Improve Anemia of CKD?Journal of clinical medicine · 2026Review
- Dangguibuxue Decoction Attenuated AA I-Induced Renal Fibrosis: Integrating Network Pharmacology and Experimental Validation.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Review
- Research Progress on the Immunomodulatory Effects by Dang Gui (Molecules (Basel, Switzerland) · 2026Review
- The pathological mechanisms and potential therapeutic strategies for renal anemia.Frontiers in pharmacology · 2026Review
- Chinese herbal medicine alleviates renal impairment induced by immunosuppressants in patients post living donor liver transplantation.Journal of traditional and complementary medicine · 2025Article
- Research on mammary gland hyperplasia compound patents' herbal combination rules based on complex system entropy clustering: A review.Medicine · 2025Review
- Homeopathy for Heteropathy: FSS and Its Components for the Treatment of Alzheimer's Disease and Endometriosis.Drug design, development and therapy · 2025Review
- Procyanidin displayed a synergistic effect with roxadustat on renal anemia in mice.Frontiers in pharmacology · 2025Article
- Stabilizing Hypoxia-Inducible Factor to Manage Anemia in Chronic Kidney Disease: From Basic Theory to Clinical Study.Kidney diseases (Basel, Switzerland) · 2024Review
- Oral administration of ethanol extract fromFrontiers in pharmacology · 2024Article
- Pharmacological action ofFrontiers in pharmacology · 2024Review
- Pharmacodynamics Research on Danggui-Shaoyao-San through Body Fluid Indexes of Spleen Deficiency-water Dampness Rats using Bio-impedance Technology.Current pharmaceutical biotechnology · 2024Article
- Article
- Exploring the Palynological, Chemical, and Bioactive Properties of Non-Studied Bee Pollen and Honey from Morocco.Molecules (Basel, Switzerland) · 2022Article
- Effect of Erythropoietin on Calcification of Vascular Smooth Muscle Cells and Its Molecular Regulatory Mechanism.Journal of cardiovascular translational research · 2021Article
- Iron metabolism and management: focus on chronic kidney disease.Kidney international supplements · 2021Article
- Screening study of blood-supplementing active components in water decoction ofPharmaceutical biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the limited efficacy and potential disadvantages of erythropoiesis-stimulating agents (ESAs) in treating anemia of chronic kidney disease (CKD), the development of better alternative therapies has become a priority. The primary purpose of this study is to investigate the effects of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.